Suppr超能文献

瑞士循环死亡后供体的胰肾联合移植

Simultaneous Pancreas and Kidney Transplantation from Donors after Circulatory Death in Switzerland.

作者信息

Rössler Fabian, Kalliola Fiona, de Rougemont Olivier, Hübel Kerstin, Hügli Sandro, Viggiani d'Avalos Lorenzo, Schachtner Thomas, Oberholzer Jose

机构信息

Department of Surgery and Transplantation, University Hospital Zurich, 8091 Zurich, Switzerland.

Department of Nephrology, University Hospital Zurich, 8091 Zurich, Switzerland.

出版信息

J Clin Med. 2024 Jun 16;13(12):3525. doi: 10.3390/jcm13123525.

Abstract

Simultaneous pancreas and kidney transplantation (SPK) remains the only curative treatment for type I diabetics with end-stage kidney disease. SPK using donors after circulatory death (DCD) is one important measure to expand the organ pool for pancreas transplantation (PT). After initial doubts due to higher complications, DCD SPK is now considered safe and equivalent to donation after brain death in terms of survival and graft function. We assessed pancreas and kidney graft function, as well as complications of the first three patients who underwent a DCD SPK in Switzerland. Two transplantations were after rapid procurement, one following normothermic regional perfusion (NRP). Intra- and postoperative courses were uneventful and without major complications in all patients. In the two SPK after rapid procurement, pancreas graft function was excellent, with 100% insulin-free survival, and hemoglobin A1C dropped from 7.9 and 7.5 before SPK and to 5.1 and 4.3 after three years, respectively. Kidney graft function was excellent in the first year, followed by a gradual decline due to recurrent infections. The patient, after NRP SPK, experienced short-term delayed pancreatic graft function requiring low-dose insulin treatment for 5 days post-transplant, most likely due to increased peripheral insulin resistance in obesity. During follow-up, there was persistent euglycemia and excellent kidney function. We report on the first series of DCD SPK ever performed in Switzerland. Results were promising, with low complication rates and sustained graft survival. With almost half of all donors in Switzerland currently being DCD, we see great potential for the expansion of DCD PT.

摘要

胰肾联合移植(SPK)仍然是治疗终末期肾病的I型糖尿病患者的唯一治愈性疗法。使用心脏死亡后供体(DCD)进行SPK是扩大胰腺移植(PT)器官库的一项重要措施。由于并发症较高,起初人们对此存在疑虑,但现在DCD SPK在生存和移植物功能方面被认为是安全的,且等同于脑死亡后捐赠。我们评估了瑞士首批接受DCD SPK的三名患者的胰腺和肾脏移植物功能以及并发症。两次移植是在快速获取后进行的,一次是在常温区域灌注(NRP)后进行的。所有患者的术中及术后过程均顺利,无重大并发症。在快速获取后的两次SPK中,胰腺移植物功能良好,胰岛素非依赖生存率为100%,糖化血红蛋白分别从SPK前的7.9和7.5降至三年后的5.1和4.3。肾脏移植物功能在第一年良好,随后由于反复感染逐渐下降。接受NRP SPK的患者术后经历了短期的胰腺移植物功能延迟,移植后需要低剂量胰岛素治疗5天,这很可能是由于肥胖导致外周胰岛素抵抗增加。在随访期间,血糖持续正常,肾功能良好。我们报告了瑞士首次进行的一系列DCD SPK。结果令人鼓舞,并发症发生率低,移植物持续存活。由于瑞士目前几乎一半的供体是DCD,我们认为DCD PT有很大的扩展潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d0b/11204996/af5888c23479/jcm-13-03525-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验